Market: NMS |
Currency:
Address:
📈 AARD Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$19.09
-
Upside/Downside from Analyst Target:
27.19%
-
Broker Call:
16
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for AARD
| Date | Reported EPS |
|---|
| 2025-11-13 | - |
| 2025-08-13 | -0.66 |
| 2025-05-14 | -0.71 |
| 2025-03-31 | -2.18 |
📰 Related News & Research
-
Aardvark Therapeutics, Inc. Files Form 8-K Announcing Entry Into Material Definitive Agreement – Company Details, Nasdaq Symbol AARD, and Contact Information
March 24, 2026
Aardvark Therapeutics, Inc. Enters \$150 Million Equity Dist...
-
Aardvark Therapeutics Pauses Phase 3 Trials for ARD-101 in Prader-Willi Syndrome, Reports 2025 Financial Results and Pipeline Updates
March 24, 2026
Aardvark Therapeutics Q4 and Full Year 2025 Financial Result...
-
Aardvark Therapeutics, Inc. – Clinical-Stage Biopharma Advancing TAS2R Small-Molecule Therapies for Obesity and Metabolic Diseases
March 24, 2026
Aardvark Therapeutics 2025 Annual Report – Key Highlights fo...
-
Aardvark Therapeutics Voluntarily Pauses Phase 3 HERO Trial for Prader-Willi Syndrome Due to Cardiac Safety Signals 1
February 28, 2026
Aardvark Therapeutics Voluntarily Pauses Phase 3 HERO Trial ...
🔍 View more Reports
